Trying Not to Melt During Summer Heat Waves? Check Out These 9 Cooling Products
Here are nine items you can use to survive this year's heat waves and summer highs.
1. Cooling towels
A handheld towel is excellent for drying off after exercising, playing sports or doing hard work under the sun. A cooling towel is a step above. Just get these towels wet with cold water and wring out the extra water. Then, wrap the cooling towel around your neck or dab your face; it should stay cool for up to 2 hours. When it starts to warm up again, just add more water and repeat the process.
These towels are great for a hot, summertime walk, relaxing at the beach or a long hike up the mountains.
Mission Mission Cool Anywhere Towels
These reusable, two-pack microfiber towels come in two different colors. They also offer UPF 50 sun protection. $23 at Mission
2. Electrolyte powder
When you spend lots of time in the heat, your body actively loses water and electrolytes -- minerals found in the body that have a charge -- through sweat. It's important to replace that lost water and electrolytes with fluids. If you struggle to drink eight cups of water a day in the summer (and sometimes you need more if you're extremely active in the heat), an electrolyte drink can help replenish your body.
The best electrolyte powders usually contain sodium, calcium, potassium, phosphate, chloride or magnesium. Electrolytes such as these can balance your body's water and pH levels, move nutrients throughout your cells, carry out waste from your cells, and ensure all muscles, bodily functions and nerves are working correctly.
Amazon/Screenshot by CNET Liquid I.V. Hydration Multiplier
Liquid I.V. powder provides two times faster hydration than water alone. It includes five vitamins and and many electrolytes.
One bag of Liquid I.V. includes 16 on-the-go packets. Add one packet to 16 ounces of water and stir.
$23 at Amazon
3. Reusable water bottle
Rule No. 1 for surviving the heat: drink lots of water. Whether this is water or an electrolyte drink, hydration in the summer is key. You don't want to become dehydrated. Dehydration symptoms include tired, dark yellow urine, sunken eyes, headache and lightheadedness.
I find that I drink the most water when I carry a water bottle around with me. I also drink more water when it stays ice cold throughout the day. An insulated stainless steel water bottle will do just that.
Amazon/Screenshot by CNET Hydro Flask
Choose between an 18-, 21- or 24-ounce Hydro Flask. Made with Pro-Made stainless steel, this water bottle is non-free, BPA-free and keeps water cold for up to 24 hours. $45 at Amazon
4. Portable fan
A portable fan is handy when you miss the indoors or are dealing with broken AC. Cool down while walking, traveling or doing anything in the sun. It can even be useful for summer camping or hanging at the beach.
Look for a portable fan that is easily rechargeable. Some fans can even mist your face.
Amazon/Screenshot by CNET JISULIFE Handheld Mini Fan
This chargeable, handheld fan is also a flashlight and a portable charger. Speed one can last up to 21 hours between charging and speed two can last up to 14 hours.
$13 at Amazon
5. Sunscreen
If you want to beat the heat, you first need to make sure your skin is protected. Wearing sunscreen should always be a priority if you're doing anything outside this summer. In addition to wearing sunglasses, a hat or UV protective clothing, sunscreen provides a shield to your delicate skin. Sunscreen provides protection from sun cancer, signs of sun damage and premature aging.
You can try chemical, mineral or combo sunscreen. If you want a sunscreen that won't leave a white cast, look for a product with a light serum. If you have acne-prone skin, use a sensitive mineral or combo sunscreen.
Amazon/Screenshot by CNET Neutrogena Mineral UltraSheer Dry-Touch Sunscreen
Neutrogena Mineral UltraSheer Dry-Touch is lightweight, clean and contains SPF 30. It is water-resistant for up to 80 minutes.
$9 at Amazon
6. Countertop ice machine
There is nothing better than an ice-cold drink on a hot day. A countertop ice machine can bring the ice directly to you. You can add ice to your water or store beverages and take them with you; a countertop ice machine can be transported from one place to another. Take it camping orbring it to an outdoor party. You can have cold ice handy as long as you have access to an outlet.
Amazon/Screenshot by CNET Igloo Portable Electric Countertop Ice Maker
This Igloo ice maker can make ice in two different sizes. Just add water, select your ice size and ice will be ready in 7 minutes. There are multiple self-cleaning settings.
$95 at Amazon
7. Cooling pillow
When sleeping cool, using a fan, AC or light pajamas might be your go-to solution. However, changing your bedding is another easy fix. A cooling pillow is designed not to retain any body heat and to provide as much breathability as possible. Some cooling pillows even have a cool-to-the-touch cover.
Pillows made of materials such as non-perforated and non-gel memory foam trap heat and will only make you hotter at night. Look for cooling pillows made of latex, foam, silk, cotton or bamboo. Note that the pillowcase you use may affect the cooling sensation of any pillow. I recommend looking for a silk, satin or light cotton pillowcase to accompany your cooling pillow.
8. Neck fan
Why hold a fan in front of your face when one can sit on your neck? If you're working outside or have your hands full, a neck fan is practical. Shaped like headphones, neck fans wrap around the neck and both sides blow up toward the sides of your face and back of your neck. It's perfect for sitting inside without AC or working under the sun.
Amazon/Screenshot by CNET ASNUG Neck Fan
The ASNUG Neck Fan is blade-less, meaning that it won't snag hair, fingers or clothing. It has three settings and is rechargable via USB. $24 at Amazon
9. Cold facial mask
A fun way to cool down is to use a cold facial mask. While I don't recommend wearing this outside, a cold compress can help calm hot, sweaty skin and bring down your internal temperature after being outside in the sun. Similar to cold rollers or certain eye creams, a cold face mask can even help depuff eyes. And if you are prone to migraines, a cold facial mask can aid a pounding headache.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Leap Therapeutics Reports Second Quarter 2025 Financial Results
CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap Highlights: Board of Directors initiated process of exploring strategic alternatives to maximize shareholder value Strategic restructuring to prioritize corporate development resulting in a further 75% reduction in workforce Reported updated data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC) "This past quarter, we undertook a strategic realignment to focus our resources on corporate development opportunities for sirexatamab and FL-501," said Douglas E. Onsi, President and CEO of Leap Therapeutics. "As part of this effort, we completed patient treatment in the DeFianCe trial, further reduced internal expenses, and initiated a review of strategic alternatives to maximize value for our shareholders. We intend to provide a further update in the coming weeks. We are grateful to all of our team members, and we thank them for their important contributions to Leap and their commitment to developing new therapies for cancer patients." DKN-01 Development Update Reported updated clinical data from Part B of the DeFianCe study of sirexatamab plus bevacizumab and chemotherapy in CRC patients. In the updated analysis as of May 22, 2025, sirexatamab demonstrated a statistically significant benefit on overall response rate (ORR), by investigator assessment and blinded independent central review, and progression-free survival (PFS) in patients with high levels of DKK1, no prior exposure to anti-VEGF therapy, or liver metastasis, along with a positive trend on ORR and PFS in the full intent-to-treat population. The final data from the study is being prepared for presentation at a future medical conference. Business Updates Exploring strategic alternatives to preserve and maximize shareholder value. The Board of Directors initiated a process to explore strategic alternatives to preserve and maximize shareholder value, including leveraging its cash balance and exploring potential sale or partnership opportunities for sirexatamab and FL-501. The Company's Board of Directors has approved the engagement of Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist in the strategic evaluation process. Taking additional steps to reduce spending and preserve capital. The Company implemented an additional workforce reduction of approximately 75%. The total costs related to this reduction in force, including severance payments, are estimated to be approximately $4.5 million. The majority of these costs will be recognized in the third and fourth quarters of 2025. Selected Second Quarter 2025 Financial Results Net Loss was $16.6 million for the second quarter 2025, compared to $20.4 million for the second quarter 2024. The decrease was primarily due to a decrease in research and development and general and administrative expenses, offset in part by a restructuring charge associated with the reduction in force. Research and development expenses were $10.5 million for the second quarter of 2025, compared to $17.9 million for the same period in 2024. The decrease of $7.4 million was primarily due to decreases of $3.9 million in clinical trial costs, $1.7 million in payroll and other headcount related expenses, $1.4 million in manufacturing costs, and $0.4 million in stock-based compensation expense. General and administrative expenses were $1.8 million for the second quarter 2025, compared to $3.4 million for the same period in 2024. The decrease of $1.6 million was primarily due to decreases of $1.4 million in payroll and other incentive based compensation expense and a $0.2 million decrease in stock-based compensation expense. During the second quarter of 2025, we incurred $4.5 million of restructuring charges associated with our workforce reduction, consisting primarily of one-time employee severance and benefit costs. Cash and cash equivalents totaled $18.1 million on June 30, 2025. About Leap TherapeuticsLeap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's pipeline includes sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, and FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein. For more information about Leap Therapeutics, visit or view our public filings with the SEC that are available via EDGAR at or via FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements within the meaning of the federal securities laws. Such statements are based upon current plans, estimates and expectations of the management of Leap that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding the potential safety, efficacy, and regulatory and clinical progress of Leap's product candidates, including sirexatamab and FL-501; Leap's plan to reduce clinical and operational activities, reduce spending and conserve cash, explore strategic alternatives to preserve and maximize shareholder value, including by leveraging its cash balance and potentially selling or partnering sirexatamab or FL-501; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Leap's plans, estimates or expectations could include, but are not limited to: (i) Leap's ability to successfully sell or enter into partnerships for sirexatamab or FL-501; (ii) the cost and timeline to complete the DeFianCe Study and wind-down operations; (iii) any regulatory feedback that Leap may receive from U.S. Food and Drug Administration (FDA) or equivalent foreign regulatory agency or from site institutional review boards; and (iv) the availability of strategic alternatives that would preserve or generate any shareholder value. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Leap may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Leap's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither Leap, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Leap's views as of any date subsequent to the date hereof. CONTACT: Douglas E. OnsiPresident & Chief Executive OfficerLeap Therapeutics, Inc.617-714-0360donsi@ Matthew DeYoungInvestor RelationsArgot Partners212-600-1902leap@ Leap Therapeutics, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited)Three Months Ended June 30, Six Months Ended June 30, 2025202420252024 Operating expenses: Research and development$ 10,537$ 17,885$ 23,448$ 29,184 General and administrative 1,817 3,367 4,823 6,893 Restructuring charges 4,527 — 4,527 — Total operating expenses 16,881 21,252 32,798 36,077 Loss from operations (16,881) (21,252) (32,798) (36,077) Interest income 246 865 683 1,640 Interest expense (7) — (13) — Australian research and development incentives 1 253 56 499 Foreign currency gain (loss) (2) 6 (6) (10) Net loss$ (16,643)$ (20,128)$ (32,078)$ (33,948) Dividend attributable to down round feature of warrants — (234) — (234) Net loss attributable to common stockholders$ (16,643)$ (20,362)$ (32,078)$ (34,182)Net loss per share Basic and diluted$ (0.40)$ (0.52)$ (0.78)$ (1.01)Weighted average common shares outstanding Basic and diluted 41,444,979 39,122,662 41,357,423 33,830,083 Leap Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts)June 30, December 31, 20252024 Assets Current assets: Cash and cash equivalents$ 18,130$ 47,249 Research and development incentive receivable 739 704 Prepaid expenses and other current assets 292 86 Total current assets 19,161 48,039Right of use assets, net 38 262 Research and development incentive receivable, net of current portion 59 — Deposits 784 823 Total assets$ 20,042$ 49,124Liabilities and Stockholders' Equity Current liabilities: Accounts payable$ 7,339$ 4,743 Accrued expenses 6,623 8,536 Income tax payable 324 531 Lease liability - current portion 39 266 Total current liabilities 14,325 14,076 Stockholders' equity: Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively — — Common stock, $0.001 par value; 240,000,000 shares authorized; 41,439,529 and 38,329,894 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 41 38 Additional paid-in capital 505,207 502,501 Accumulated other comprehensive loss (82) (120) Accumulated deficit (499,449) (467,371) Total stockholders' equity 5,717 35,048 Total liabilities and stockholders' equity $ 20,042$ 49,124 Leap Therapeutics, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) (Unaudited) Three Months Ended June 30 Six Months Ended June 30 20252024 20252024 Cash used in operating activities $ (14,486)$ (13,671) $ (28,966)$ (29,187) Cash provided by (used in) financing activities (119)37,117 (180)37,146 Effect of exchange rate changes on cash and cash equivalents 22112 27(123) Net increase (decrease) in cash and cash equivalents (14,583)23,558 (29,119)7,836 Cash and cash equivalents at beginning of period 32,71354,921 47,24970,643 Cash and cash equivalents at end of period $ 18,130$ 78,479 $ 18,130$ 78,479 View original content to download multimedia: SOURCE Leap Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Infectious Disease Therapies Market Projected to Reach $101 Billion by End of 2030
"As infectious diseases like HIV, hepatitis, tuberculosis, and influenza continue to challenge global health systems, new breakthroughs such as long acting injectables and monoclonal antibodies are driving better patient outcomes and fueling market growth, especially in the face of rising drug resistance." BOSTON, Aug. 14, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Global Markets for Infectious Disease Treatments" is expected to grow from $72.5 billion in 2025 to $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030. This report analyzes the global market for infectious disease therapeutics, vaccines, and diagnostics, covering diseases such as HIV, influenza, hepatitis B and C, RSV, TB, HSV, malaria, rotavirus, and viral hemorrhagic fevers. It highlights market trends, challenges, and opportunities, along with insights into new products, acquisitions, collaborations, and ESG developments. The report also ranks leading companies by market share and provides detailed profiles of them. Excluded from the report are vector control strategies, symptomatic treatments, generic suppliers, and certain hospital-based diagnostic methods. This report is particularly relevant today because the COVID-19 pandemic has reshaped global priorities around infectious diseases. It exposed critical gaps in healthcare systems and underscored the urgent need for rapid diagnostics, effective treatments, and scalable vaccine platforms. In response, governments, organizations, and private companies invested in infectious disease research and infrastructure, driving innovation and global collaboration. The pandemic also highlighted the importance of early detection, surveillance, and preparedness, leading to renewed attention on emerging and neglected infectious diseases. The factors driving the market's growth include: Increasing Resistance to Drugs: Drug resistance is rising as bacteria and viruses evolve to withstand existing treatments, making infections harder to cure. This pushes pharmaceutical companies to develop new drugs and therapies, driving growth in the infectious disease treatment market. Global Efforts to Combat Infectious Diseases: Governments and international organizations are investing in public health initiatives, research, and vaccination programs to control infectious diseases. These efforts create strong support for treatment development and expand market opportunities worldwide. Technological Advances in Diagnostics and Therapeutics: Innovations like rapid testing, AI-based drug discovery, and advanced vaccines are improving how diseases are detected and treated. These technologies enhance efficiency and effectiveness, boosting demand for more effective diagnostic and therapeutic solutions. Climate Change: Changing climate patterns are expanding the reach of disease-carrying organisms, leading to the spread of infections in new regions. This increases the need for treatments in previously unaffected areas, stimulating market expansion and adaptation. Request a sample copy of the global market for infectious disease treatments report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $68.3 billion Market size forecast $101 billion Growth rate CAGR of 6.9% for the forecast period of 2025-2030 Segments covered Product, Disease, and Region Regions covered North America, Europe, Asia-Pacific, Middle East and Africa, and South America Countries covered U.S., Canada, Mexico, U.K., Germany, France, China, India, and Japan Market drivers • Increasing resistance to drugs. • Global efforts to combat infectious diseases. • Technological advances in diagnostics and therapeutics. • Climate change. • Increase in international travel. Interesting facts: More than 85% of hepatitis B virus infections never receive a diagnosis. Due to climate change, mosquito-borne infectious diseases are on the rise. The worldwide incidence of dengue has risen eightfold in the past 20 years. Emerging startups: Codagenix: The company develops vaccines and viral therapeutic candidates for infectious diseases. Its intranasal vaccine candidate, CoviLiv, is a live-attenuated vaccine against COVID-19. nChroma Bio: A biotechnology company advancing genetic medicines. CRMA-1001 is an epigenetic editor in development as a potential treatment for chronic hepatitis B and hepatitis D. The company plans to submit a clinical trial application in 2025. The report addresses the following questions: What are the projected size and growth rate of the Infectious disease treatments market?- The global Infectious disease treatments market was estimated at $68.3 billion in 2024. The market is projected to reach $101 billion in 2030, growing at a CAGR of 6.9% during the forecast period. Which market segments are covered in the report?- The report includes historical data and market projection on sales by product type, disease, and region. Which product type segment will be dominant through 2030?- Therapeutics is expected to have the largest share of the product type segment through the end of 2030. Which product type is showing the fastest growth?- The vaccine segment is the fastest growing product type segment. What are the key challenges and opportunities in the market?- Challenges: Pricing pressure is a significant factor restraining the growth of the infectious disease treatment market, particularly in low and middle-income countries where healthcare budgets are limited. Lack of awareness and underdiagnosis remain major barriers to the growth of the infectious disease treatment market.- Opportunities: Self-testing kits are rapidly gaining traction in the field of infectious diseases, offering individuals convenient, private, and timely diagnostic options. Market leaders include: ABBOTT ABBVIE INC. CSL DANAHER CORP. F. HOFFMANN-LA ROCHE LTD. GILEAD SCIENCES INC. GSK PLC JOHNSON & JOHNSON MERCK & CO. INC. MOLBIO DIAGNOSTICS LTD. ORASURE TECHNOLOGIES INC. PFIZER INC. SANOFI SERUM INSTITUTE OF INDIA PVT. LTD. SIEMENS HEALTHINEERS Related reports: The Global Influenza Market: This report provides a comprehensive review of the global influenza market, offering qualitative and quantitative insights. It explores the historical context of flu pandemics, current disease burden, and vaccine coverage across key regions. The market is segmented into vaccines (inactivated and live-attenuated), therapeutics, and diagnostics (rapid and conventional tests), with detailed analysis of each category. It also highlights leading products, clinical trials, new approvals, and emerging technologies. Regional demographics and growth prospects in North America, Europe, and Asia-Pacific are examined, along with strategic profiles of major companies operating in the influenza sector. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "BrainStorm remains focused on executing our clinical development plan for NurOwn®. We reached an important milestone in Q2 with FDA clearance to initiate our Phase 3b trial, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We are also advancing key operational activities, including discussions with clinical sites as well as ongoing engagement with our selected CDMO partners to ensure readiness for clinical drug supply. We are encouraged by the ongoing interest and support from clinicians and the ALS community, and we remain confident that, if approved, NurOwn has the potential to make a meaningful difference for patients and their families." Mr. Lebovits continued, "We support the FDA's consideration of the Citizen Petition, which may provide a fresh opportunity for an objective evaluation of the scientific evidence. We continue to stand behind the integrity and rigor of our data and will continue to engage with clinicians and the ALS community." Recent Highlights NurOwn (MSC-NTF) for ALS FDA has cleared the company to initiate the Phase 3b clinical trial of NurOwn® The Phase 3b trial, known as ENDURANCE, is expected to enroll approximately 200 participants at leading academic medical centers and will consist of a 24-week randomized, double-blind, placebo-controlled phase, followed by a 24-week open-label extension in which all participants will receive NurOwn. The primary endpoint is the change from baseline to week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R). Successful completion of the double blind portion of the study (Part A) is expected to generate the clinical data needed to support a new BLA submission. Details of the trial, including a list of anticipated participating clinical sites, are available on ID NCT06973629. A Citizens Petition submitted to the FDA by ALS Community requesting a new review of the NurOwn data The company acknowledges that the FDA's consideration of the petition provides a new opportunity to reaffirm NurOwn's potential as a therapy for ALS. BrainStorm was not involved in drafting or submitting this petition or its contents. New survival data from NurOwn Expanded Access Program show that 100% of participants (10/10) in the EAP survived more than 5 years from the onset of ALS symptoms, compared to published estimates indicating that approximately 10% of individuals with ALS would survive beyond 5 years. The single death in the cohort occurred following elective euthanasia. The median survival observed in the EAP cohort was 6.8 years (range: 6 to 7 years) from symptom onset. Although the EAP cohort included participants earlier in their disease course, these results are encouraging and support further study. Manufacturing Partnership with Minaris BrainStorm has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn for the upcoming Phase 3b clinical trial. NurOwn® data selected as Breakthrough Science for Presentation at ISCT 2025 Meeting The new pharmacogenomic data were delivered in an oral presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting in May 2025, in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for ALS patients treated with NurOwn. The presentation was featured in the ISCT public announcement regarding the meeting, which indicated that the data were "carefully reviewed and selected by the ISCT 2025 Planning Faculty, to explore the latest breakthroughs in the clinical translation of Mesenchymal Stem/Stromal Cells and how they will shape the future of cell therapies." Financial Results for the Second quarter Ended June 30, 2025 Cash, cash equivalents, and restricted cash were approximately $1.03 million as of June 30, 2025. Research and development expenditures, net, for the quarter ended June 30, 2025 were $1.1 million, compared to $0.9 million for the quarter ended June 30, 2024. General and administrative expenses for the quarter ended June 30, 2025 were approximately $1.4 million, compared to approximately $2.1 million for the quarter ended June 30, 2024. Net loss for the quarter ended June 30, 2025, was approximately $2.9 million, as compared to a net loss of approximately $2.5.4 million for the quarter ended June 30, 2024. Net loss per share for the three months ended June 30, 2025, and 2024 was $0.34 and $0.60, respectively. Conference Call and Webcast Participant Numbers: Toll Free 877-545-0320 International 973-528-0002 Participant Access Code 601260 Webcast The replay of the conference call can be accessed by dialing the numbers below and will be available until August 28. Replay Numbers: Toll Free 877-481-4010 International 919-882-2331 Reply Passcode 52831 About NurOwn® The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" — a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit Notice Regarding Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. CONTACTS Investors:Michael WoodPhone: +1 646-597-6983mwood@ Media: Uri Yablonka, Chief Business OfficerPhone: +1 917-284-2911uri@ CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (Except share data) June 30,December 31, 20252024 UnauditedAudited U.S. $ in thousands ASSETSCurrent Assets: Cash and cash equivalents$ 824$ 187 Other accounts receivable 106 63 Prepaid expenses and other current assets 585 135 Total current assets$ 1,515$ 385Long-Term Assets: Prepaid expenses and other long-term assets $ 24$ 22 Restricted Cash 201 184 Operating lease right of use asset (Note 3) 495 807 Property and Equipment, Net 331 434 Total Long-Term Assets$ 1,051$ 1,447Total assets$ 2,566$ 1,832LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current Liabilities: Accounts payables$ 5,997$ 6,080 Accrued expenses 367 619 Short-term loans (Note 7) 101 300 Operating lease liability (Note 3) 381 549 Employees related liability 1,682 1,430 Total current liabilities$ 8,528$ 8,978Long-Term Liabilities: Operating lease liability (Note 3) 95 171 Warrants liability (Note 4) - 447 Total long-term liabilities$ 95$ 618Total liabilities$ 8,623$ 9,596Stockholders' Deficit: Stock capital: (Note 5) 16 14 Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at June 30, 2025 and at December 31, 2024 respectively; Issued and outstanding: 10,120,109 and 6,141,762 shares at June 30, 2025 and December 31, 2024 respectively Additional paid-in-capital 226,446 218,974 Treasury stocks (116) (116) Accumulated deficit (232,403) (226,636) Total stockholders' deficit$ (6,057)$ (7,764)Total liabilities and stockholders' deficit$ 2,566$ 1,832 BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) U.S. dollars in thousands (Except share data) Six months ended Three months ended June 30, June 30, 2025202420252024 UnauditedUnaudited Operating expenses:Research anddevelopment, net$ 2,424$ 1,883$ 1,120$ 922 General and administrative 3,238 3,573 1,453 2,060Operating loss (5,662) (5,456) (2,573) (2,982)Financial income (expense), net (284) 43 (330) 30Gain (loss) on change in fair value of Warrants liability (Note 4) 179 529 - (411)Net loss$ (5,767)$ (5,942)$ (2,903)$ (2,541)Basic and diluted net lossper share from continuing operations$ (0.77)$ (1.35)$ (0.34)$ (0.60)Weighted average numberof shares outstanding usedin computing basic and diluted net loss per share 7,487,495 4,531,801 8,620,400 4,747,699 Logo - View original content to download multimedia: SOURCE BrainStorm Cell Therapeutics Inc.
